NASDAQ:ADAP
Delisted

Adaptimmune Therapeutics Stock News

etoro logo Buy ADAP
*Your capital is at risk
$0.0549
+0 (+0%)
At Close: Feb 20, 2026
Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) has earned an average rating of “Buy” from the eight ratings firms that are presently covering the company, Marketbeat.com reports. Three equities re
In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on T2 Biosystems (TTOO – Research Report).
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zogenix (ZGNX
After William Blair and Needham gave Autolus Therapeutics (NASDAQ: AUTL) a Buy rating last month, the company received another Buy,
Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on Neoleukin Therapeutics (NLTX – Research Report) yesterday and set a
JonesTrading analyst Soumit Roy initiated coverage with a Buy rating on Curis (CRIS – Research Report) today and set a
The lobster industry has been hit hard this year. Here's a recipe to help you do your bit to help them.
Au sommaire du Café des sports: 1/ Coupe d’Italie, Naples vainqueur ! La ville en liesse. La victoire d’un entraîneur Gennaro Gattuso ?
Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on Autolus Therapeutics (AUTL – Research Report) today and set a

A Few Top Charts

12:00am, Friday, 19'th Jun 2020
Stocks Analysis by Harry Boxer covering: Bed Bath & Beyond Inc, Ballard Power Systems Inc, Apache Corporation, Arena Pharmaceuticals Inc. Read Harry Boxer's latest article on Investing.com
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Armata Pharmaceuticals
As of late, it has definitely been a great time to be an investor in Adaptimmune Therapeutics plc (ADAP).
Adaptimmune Therapeutics (ADAP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Albireo Pharma
GlaxoSmithKline's years-long oncology resurgence is on track to have two new drugs approved in the US in mid-2020, after the company won a key first-line
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE